FindTrial
Sign In

A Randomized Controlled Study on the Efficacy of Liver Resection and TACE Combined with Radiotherapy in Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombus

A Multicenter Prospective Randomized Controlled Study the Efficacy of Liver Resection and TACE Combined with Radiotherapy in Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombus

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041314
Enrollment
Unknown
Registered
2020-12-23
Start date
2020-12-31
Completion date
Unknown
Last updated
2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma, combined portal vein tumor thrombosis

Interventions

Group 1:Liver resection (LR)
Group 2:TACE+RT

Sponsors

Third Affiliated Hospital of the Second Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-70 years; 2. Patients with clinical diagnosis of hepatocellular carcinoma (clinical diagnostic criteria of hepatocellular carcinoma: in line with the diagnostic criteria of 2019 primary liver cancer diagnosis and treatment standard); 3. In the patients with clear tumor thrombus on imaging (MR or CT), the tumor thrombus did not reach the main portal vein or the opposite side (Cheng's type I, II); 5. Patients who have not received other anti-tumor therapy in the past; 6. Patients with tumor and tumor thrombus located in the ipsilateral liver and resectable (residual liver volume in patients without cirrhosis accounted for more than 30% of the standard liver volume, and residual liver volume in patients with cirrhosis accounted for more than 40% of the standard liver volume; after evaluation, postoperative liver function can be compensated.) 7. Patients with ECoG 0-2 in general condition; 8. Patients with child Pugh score a of liver function; 9. Patients who are aware of the research process and agree to participate in the study shall sign relevant informed consent documents.

Exclusion criteria

Exclusion criteria: 1. Patients with other tumor history; 2. Patients with tumor thrombus exceeding the main portal vein or to the contralateral portal vein; 3. Patients with multiple or distant intrahepatic metastases; 4. Patients with portal hypertension (PLT < 50 * 10^9 / L, gastroscopy showed severe esophagogastric varices or previous upper gastrointestinal bleeding, cavernous transformation of portal vein).

Design outcomes

Primary

MeasureTime frame
Overall Survival;—

Secondary

MeasureTime frame
Median Survival Time;—

Countries

China

Contacts

Public ContactZhou Weiping

Third Affiliated Hospital of the Second Military Medical University

ehphwp@126.com+86 13601616763

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026